Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. Chen AY, Jemal A, Ward EM (2009) Increasing incidence of differentiated thyroid cancer in the United States: 1988–2005. Cancer 115(16):3801–3807
2. Larijani B, Aghakhani S, Khajedini H, Baradar-jalili R (2003) Clinico-pathological features of thyroid cancer as observed in five referral hospitals in Iran: a review of 1177 cases. Actaoncol 42:337–347
3. Khayamzadeh M, Khayamzadeh M, Tadayon N, Salmanian R, Salmanian R, Zham H et al (2011) Survival of thyroid cancer and social determinants in Iran, 2001–2005. Asian Pacific J cancer Prev 12(1):95–98
4. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E (2012) Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 167(5):643–650
5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133